Relay Therapeutics focuses on drug discovery by emphasizing the movement of proteins in its research. The company uses its Dynamo™ platform, which integrates experimental and computational methods, to identify and develop new drugs, particularly for complex diseases that are hard to treat with traditional approaches. This platform enables Relay to target proteins that have previously been difficult to address, expanding treatment options, especially in precision oncology and genetic diseases. Unlike its competitors, Relay Therapeutics collaborates with major biotech firms, such as Genentech, to validate its technology and generate revenue through licensing and partnerships. The main goal of Relay Therapeutics is to create impactful medicines for patients, and it is actively conducting clinical trials to ensure the safety and effectiveness of its drug candidates.